Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.
type: Dataset
description: International audience
issued: 2026-05-21T11:07:35.958949
language: en
modified: 2026-05-21T11:07:35.958956
contact point: Organization
  fn: CCSD
keyword: infoeu-reposemanticsarticle
keyword: journal-articles
keyword: mesh-anemia-hemolytic-autoimmune
keyword: mesh-antibodies-monoclonal
keyword: mesh-antibodies-monoclonal-murine-derived
keyword: mesh-cost-benefit-analysis
keyword: mesh-humans
keyword: sdvmheplife-sciences-q-biohuman-health-and-pathology
landing page: 0390-6078

Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.
type: Distribution
format: HTML
issued: 2026-05-21T11:07:35.964587
modified: 2026-05-21T11:07:35.937726
access URL: https://hal.univ-brest.fr/hal-00689153

test_moissonnage_selune
type: Agent